Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020)
Vaxcyte (PCVX) posted quarterly Preferred Stock Liabilities of $55.2 million for Q1 2020, up 46.32% year-over-year from $37.7 million in Q2 2019, and down 65.6% quarter-over-quarter from $160.3 million in Q4 2019.
Powered by 
Analysis
Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has reported Preferred Stock Liabilities for 2 consecutive years, with $55.2 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Preferred Stock Liabilities rose 46.32% year-over-year to $55.2 million; the TTM figure through Mar 2020 stood at $55.2 million (up 46.32% YoY), while the FY2019 annual figure was $160.3 million, up 190.67% from the prior year.
- Preferred Stock Liabilities fell to $55.2 million in Q1 2020 per PCVX's latest filing, from $160.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $160.3 million in Q4 2019 and bottomed at $25.0 million in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 109.88 Mn |
| Dec 31, 2019 | 160.31 Mn |
| Sep 30, 2019 | 55.15 Mn |
| Jun 30, 2019 | 55.15 Mn |
| Mar 31, 2019 | 55.15 Mn |